Mesna-Cell Stadapharm

Mesna, the active ingredient in Mesna-Cell, is a uroprotective agent presented as an injectable solution for intravenous use. It is employed to prevent hemorrhagic cystitis and other bladder toxicity that can occur during cyclophosphamide or ifosfamide chemotherapy in cancer patients.

GNH USA supplies Mesna-Cell as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mesna is a uroprotective agent that reduces chemotherapy‑induced bladder toxicity.

- Hemorrhagic cystitis (cyclophosphamide therapy): Prevents bladder inflammation and bleeding associated with cyclophosphamide chemotherapy. - Urotoxicity (ifosfamide therapy): Reduces the risk of bladder damage caused by ifosfamide treatment. - Stem‑cell transplant conditioning (high‑dose cyclophosphamide): Provides bladder protection during high‑dose cyclophosphamide regimens used for stem‑cell transplantation.

Mesna may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate nausea reported during infusion. - Vomiting: occasional vomiting following administration. - Headache: transient headache during or after dosing. - Hypotension: mild drop in blood pressure, usually self‑limiting. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decline leading to syncope. - Pulmonary edema: rare accumulation of fluid in the lungs. - Stevens‑Johnson syndrome: rare severe skin reaction.

When using Mesna, several precautions should be observed to ensure safety and effectiveness.

- Renal function: assess kidney function before initiation and monitor during therapy. - Urine alkalinization: consider alkalinizing urine to enhance acrolein detoxification. - Concomitant chemotherapy: coordinate timing with cyclophosphamide or ifosfamide to maintain protective effect. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mesna can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing sulfhydryl groups: may compete for acrolein binding and reduce protective effect. - Probenecid: can decrease renal clearance of Mesna, potentially lowering its urinary concentration.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase risk of electrolyte disturbances when combined with Mesna. - ACE inhibitors or ARBs: monitor blood pressure as additive hypotensive effects may occur. - Other sulfhydryl‑donating drugs: observe for altered pharmacodynamics.